NCT06792994Recruiting
A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG
Source: ClinicalTrials.gov · Last updated 30 Apr 2026
Brief summary (registry, in English)
This observational trial is designed to investigate long-term survival with regard to the primary endpoint overall survival (OS) after start of first-line treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 20 Jan 2025
- Start date
- 2 Apr 2026
- Primary completion date
- 1 Aug 2030
- Lead sponsor
- German CLL Study Group
- Diseases
- Chronic lymphocytic leukaemia
- NCT number
- NCT06792994
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 2 Apr 2026 to the primary completion date, 1 Aug 2030
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- • Patients without participation in one of the first-line studies of the GCLLSG (CLL13, CLL14, CLL17)
- Subjects with legal incapacity
- Subjects who are institutionalized by regulatory or court order
- Subjects who are in dependence to the sponsor or the investigator
Who the study is looking for
- • Subjects must voluntarily sign and date an informed consent, ap-proved by an independent ethics committee (IEC)/institutional review board (IRB)
- Documented diagnosis of CLL at time point of inclusion in a first-line study of the GCLLSG (development of RT is not an exclusion criterion)
- First-line treatment was administered within one of these first-line studies of the GCLLSG (CLL13, CLL14, or CLL17).
- Subsequent therapy lines were either documented during the participa-tion in a first-line study of the GCLLSG or patient consented to have the subsequent therapy lines documented within this observational trial.
- Subjects are willing and able to comply with procedures required in this protocol.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Cologne Coordinator of this site? Confirm its status | Cologne | Germany | Recruiting |
| Universitätsklinikum Ulm Coordinator of this site? Confirm its status | Ulm | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.